State of the science 60th anniversary review 60 years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal cancer

Cancer

Volumn 113, Issue 7, 2008, Pages 1728-1743

  Demierre, Marie France ^a   Sabel, Michael S ^b   Margolin, Kim A ^c   Daud, Adil I ^d   Sondak, Vernon K ^e,f  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; CARMUSTINE; CISPLATIN; DACARBAZINE; DACTINOMYCIN; FOTEMUSTINE; IFOSFAMIDE; INTERLEUKIN 2; MELPHALAN; PACLITAXEL; RECOMBINANT ALPHA INTERFERON; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE; VINBLASTINE; VINCRISTINE;

BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; DEATH; DRUG MEGADOSE; EARLY DIAGNOSIS; HIGH RISK PATIENT; HUMAN; LIVER VEIN OBSTRUCTION; MELANOMA; NAUSEA; NOTE; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; SKIN METASTASIS; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT RESPONSE; VOMITING;

HUMANS; IMMUNOTHERAPY; MELANOMA; PROGNOSIS; SKIN NEOPLASMS;

EID: 53949089178     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23643     Document Type: Note

References (193)

1. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet. 2005;365:687-701.
2. Allen AC, Spitz S. Malignant melanoma: a clinicopathological analysis of the criteria for diagnosis and prognosis. Cancer. 1953;6:1-45.
3. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.
4. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97:1488-1498.
5. Sondak VK, Taylor JMG, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11:247-258.
6. Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer. 2007;109:100-108.
7. Lasithiotakis K, Leiter U, Meier F. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer. 2008;112:1795-1804.
8. Geller AC, Miller DR, Annas GD, Demierre MF, Gilchrest BA, Koh HK. Melanoma incidence and mortality among US whites, 1969-1999. JAMA. 2002;288:1719-1720.
9. Jemal A, Devesa SS, Hartge P, Tucker MA. Recent trends in cutaneous melanoma incidence among whites in the United States. J Natl Cancer Inst. 2001;93:678-683.
10. Demierre MF, Chung C, Miller DR, Geller AC. Early detection of thick melanomas in the US? "Beware" of the nodular subtype. Arch Dermatol. 2005;141:745-750.
11. Mihm MC Jr, Fitzpatrick TB. Early detection of malignant melanoma. Cancer. 1976;37(1 suppl):597-603.
12. Wick MM, Sober AJ, Fitzpatrick TB, et al. Clinical characteristics of early cutaneous melanoma. Cancer. 1980;45:2684-2686.
13. Rigel DS, Friedman RJ, Kopf AW, Polsky D. ABCDE - an evolving concept in the early detection of melanoma. Arch Dermatol. 2005;141:1032-1034.
14. Schwartz JL, Wang TS, Hamilton TA, Lowe L, Sondak VK, Johnson TM. Thin primary cutaneous melanomas: associated detection patterns, lesion characteristics, and patient characteristics. Cancer. 2002;95:1562-1568.
15. McPherson M, Elwood M, English DR, Baade PD, Youl PH, Aitken JF. Presentation and detection of invasive melanoma in a high-risk population. J Am Acad Dermatol. 2006;54:783-792.
16. Rigel DS, Rivers JK, Kopf AW, et al. Dysplastic nevi. Markers for increased risk for melanoma. Cancer. 1989; 63:386-389.
17. Elder DE, Goldman LI, Goldman SC, Greene MH, Clark WH Jr. Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer. 1980;46:1787-1794.
18. Grob JJ, Gouvernet J, Aymar D, et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer. 1990;66:387-395.
19. Marghoob AA, Slade J, Salopek TG, Kopf AW, Bart RS, Rigel DS. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer. 1995;75(2 suppl):707-714.
20. Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer. 2003;97:639-643.
21. Hollenbeak CS, Todd MM, Billingsley EM, Harper G, Dyer AM, Lengerich EJ. Increased incidence of melanoma in renal transplantation recipients. Cancer. 2005;104:1962-1967.
22. McWhorter HE, Figi FA, Woolner LB. Treatment of juvenile melanomas and malignant melanomas in children. JAMA. 1954;156:695-698.
23. Williams HE Melanoma with fatal metastases in 5-year old girl; report of a case. Cancer. 1954;7:163-167.
24. Skov-Jensen T, Hastrup J, Lambrethsen E. Malignant melanoma in children. Cancer. 1966;19:620-626.
25. Pratt CB, Palmer MK, Thatcher N, Crowther D. Malignant melanoma in children and adolescents. Cancer. 1981;47:392-397.
26. Barnhill RL, Flotte TJ, Fleischli M, Perez-Atayde A. Cutaneous melanoma and atypical Spitz tumors in childhood. Cancer. 1995;76:1833-1845.
27. Su LD, Fullen DR, Sondak VK, Johnson TM, Lowe L. Sentinel lymph node biopsy for patients with problematic spitzoid melanocytic lesions: a report on 18 patients. Cancer. 2003;97:499-507.
28. Livestro DP, Kaine EM, Michaelson JS, et al. Melanoma in the young. Differences and similarities with adult melanoma: a case-matched controlled analysis. Cancer. 2007; 110:614-624.
29. George PA, Fortner JG, Pack GT. Melanoma with pregnancy. A report of 115 cases. Cancer. 1960;13:854-859.
30. Shaw HM, Milton GW, Farago G, McCarthy WH. Endocrine influences on survival from malignant melanoma. Cancer. 1978;42:669-677.
31. Shiu MH, Schottenfeld D, Maclean B, Fortner JG. Adverse effect of pregnancy on melanoma: a reappraisal. Cancer. 1976;37:181-187.
32. Houghton AN, Flannery J, Viola MV. Malignant melanoma of the skin occurring during pregnancy. Cancer. 1981;48:407-410.
33. Reintgen DS, McCarty KS Jr, Vollmer R, Cox E, Seigler HE Malignant melanoma and pregnancy. Cancer. 1985;55:1340-1344.
34. Daryanani D, Plukker JT, De Hullu JA, Kuiper H, Nap RE, Hoekstra HJ. Pregnancy and early-stage melanoma. Cancer. 2003;97:2248-2253.
35. Sober AJ. Diagnosis and management of skin cancer. Cancer. 1983;51(12 suppl):2448-2452.
36. Sober AJ, Fitzpatrick TB, Mihm MC, et al. Early recognition of cutaneous melanoma. JAMA. 1979;242:2795-2799.
37. Kopf AW. Prevention and early detection of skin cancer/melanoma. Cancer. 1988;62(8 suppl):1791-1795.
38. Kopf AW, Kripke ML, Stern RS. Sun and malignant melanoma. J Am Acad Dermatol. 1984;11:674-684.
39. Geller AC, Swetter SM, Brooks K, Demierre MF, Yaroch AL. Screening, early detection, and trends for melanoma: current status (2000-2006) and future directions. J Am Acad Dermatol. 2007;57:555-572.
40. Koh HK, Caruso A, Gage I, et al. Evaluation of melanoma/skin cancer screening in Massachusetts. Preliminary results. Cancer. 1990;65:375-379.
41. McDonald CJ. Status of screening for skin Cancer. Cancer. 1993;72(3 suppl):1066-1070.
42. Rhodes AR. Public education and cancer of the skin. What do people need to know about melanoma and nonmelanoma skin cancer? Cancer. 1995;75(2 suppl):613-636.
43. Koh HK, Geller AC, Miller DR, Lew RA. The early detection of and screening for melanoma. International status. Cancer. 1995;75(2 suppl):674-683.
44. Geller AC, Sober AJ, Zhang Z, et al. Strategies for improving melanoma education and screening for men age ≥50 years: findings from the American Academy of Dermatological National Skin Cancer Screening Program. Cancer. 2002;95:1554-1561.
45. Janda M, Youl PH, Lowe JB, et al. What motivates men age ≥50 years to participate in a screening program for melanoma? Cancer. 2006;107:815-823.
46. Demierre MF. Thin melanomas and regression, thick melanomas and older men: prognostic implications and perspectives on secondary prevention. Arch Dermatol. 2002; 138:678-682.
47. Geller AC, Emmons KM, Brooks DR, et al. A randomized trial to improve early detection and prevention practices among siblings of melanoma patients. Cancer. 2006;107:806-814.
48. Berwick M, Begg CB, Fine JA, Roush GC, Barnhill RL. Screening for cutaneous melanoma by skin self-examination. J Natl Cancer Inst. 1996;88:17-23.
49. Brady MS, Oliveria SA, Christos PJ, et al. Patterns of detection in patients with cutaneous melanoma. Cancer. 2000;89:342-347.
50. Rang S, Barnhill RL, Mihm MC Jr, Sober AJ. Multiple primary cutaneous melanomas. Cancer. 1992;70:1911-1916.
51. Burden AD, Newell J, Andrew N, Kavanagh G, Connor JM, MacKie RM. Genetic and environmental influences in the development of multiple primary melanoma. Arch Dermatol. 1999;135:261-265.
52. Conrad N, Leis P, Orengo I, et al. Multiple primary melanoma. Dermatol Surg. 1999;25:576-581.
53. Blackwood MA, Holmes R, Synnestvedt M, et al. Multiple primary melanoma revisited. Cancer. 2002;94:2248-2255.
54. Conley J, Lattes R, Orr W. Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). Cancer. 1971;28:914-936.
55. Valensi QJ. Desmoplastic malignant melanoma: a light and electron microscopic study of two cases. Cancer. 1979; 43:1148-1155.
56. Carlson JA, Dickersin GR, Sober AJ, Barnhill RL. Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases. Cancer. 1995;75:478-494.
57. Quinn MJ, Crotty KA, Thompson JF, et al. Desmoplastic and desmoplastic neurotropic melanoma. Experience with 280 patients. Cancer. 1998;83:1128-1135.
58. Arora A, Lowe L, Su L, et al. Wide excision without radiation for desmoplastic melanoma. Cancer. 2005;104:1462-1467.
59. Pawlik TM, Ross MI, Prieto VG, et al. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer. 2006;106:900-906.
60. Livestro DP, Muzikansky A, Kaine EM, et al. Biology of desmoplastic melanoma: a case-control comparison with other melanomas. J Clin Oncol. 2005;23:6739-6746.
61. Su LD, Fullen DR, Lowe L, et al. Desmoplastic and neurotropic melanoma. Analysis of 33 patients with lymphatic mapping and sentinel lymph node biopsy. Cancer. 2004; 100:598-604.
62. Gromet MA, Epstein WL, Blois MS. The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer. 1978;42:2282-2292.
63. Shafir R, Hiss J, Tsur H, Bubis JJ. The thin malignant melanoma: changing patterns of epidemiology and treatment. Cancer. 1982;50:817-819.
64. Naruns PL, Nizze JA, Cochran AJ, Lee MB, Morton DL. Recurrence potential of thin primary melanomas. Cancer. 1986;57:545-548.
65. Kelly JW, Sagebiel RW, Blois MS. Regression in malignant melanoma. A histologic feature without independent prognostic significance. Cancer. 1985;56:2287-2291.
66. Leiter U, Buettner P, Eigentler TK, Garbe C. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the German Dermatological Society. J Clin Oncol. 2004;22:3660-3667.
67. Kaur C, Thomas R, Desai N, et al. The correlation of regression in primary melanoma with sentinel lymph node status. J Clin Pathol. 2008;61:297-300.
68. Puleo CA, Messina JL, Riker AI, et al. Sentinel node biopsy for thin melanomas: which patients should be considered? Cancer Control. 2005;12:230-235.
69. Messina JL, Sondak VK. Prognostic factors in localized cutaneous melanoma with particular reference to thin primary lesions. Ital J Dermatol Venereol. 2007;142:123-129.
70. Gimotty PA, Guerry D, Ming ME, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol. 2004;22:3668-3676.
71. Cassileth BR, Clark WH Jr, Heiberger RM, March V, Tenaglia A. Relationship between patients' early recognition of melanoma and depth of invasion. Cancer. 1982;49:198-200.
72. Liu W, Dowling JP, Murray WK, et al. Rate of growth in melanomas. Arch Dermatol. 2006;142:1551-1558.
73. Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003;95:1878-1890.
74. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135-2147.
75. Masback A, Westerdahl J, Ingvar C, Olsson H, Jonsson N. Cutaneous malignant melanoma in south Sweden 1965, 1975, and 1985. A histopathologic review. Cancer. 1994;73:1625-1630.
76. Masback A, Westerdahl J, Ingvar C, Olsson H, Jonsson N. Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985. Prognostic factors and histologic correlations. Cancer. 1997;79:275-283.
77. Lasithiotakis KG, Leiter U, Eigentler T, et al. Improvement of overall survival of patients with cutaneous melanoma in Germany, 1976-2001: which factors contributed? Cancer. 2007;109:1174-1182.
78. Buettner PG, Leiter U, Eigentler TK, Garbe C. Development of prognostic factors and survival in cutaneous melanoma over 25 years: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. Cancer. 2005;103:616-624.
79. Koh HK, Sober AJ, Day CL Jr, Lew RA, Fitzpatrick TB. Cigarette smoking and malignant melanoma. Prognostic implications. Cancer. 1984;53:2570-2573.
80. Odenbro A, Gillgren P, Bellocco R, Boffetta P, Hakansson N, Adami J. The risk for cutaneous malignant melanoma, melanoma in situ and intraocular malignant melanoma in relation to tobacco use and body mass index. Br J Dermatol. 2007;156:99-105.
81. Gilchrest BA. Sun protection and Vitamin D: three dimensions of obfuscation. J Steroid Biochem Mol Biol. 2007;103:655-663.
82. Binkley N, Novotny R, Krueger D, et al. Low vitamin D status despite abundant sun exposure. J Clin Endocrinol Metabol. 2007;92:2130-2135.
83. Essner R. Surgical treatment of malignant melanoma. Surg Clin North Am. 2003;83:109-156.
84. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg. 1991;126:438-441.
85. Batch CM, Soong S-J, Ross MI, et al. Long-term results of a prospective surgical trial comparing 2 cm vs 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol. 2001;8:101-108.
86. Thomas JM, Newton-Bishop J, A'Hern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med. 2004;350:757-766.
87. Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Group on 2 cm vs 5 cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer. 2000;89:1495-1501.
88. Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1 mm thick). Cancer. 2003;97:1941-1946.
89. Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma. Cancer. 2000;89:1019-1025.
90. Shen P, Conforti AM, Essner R, et al. Is the node of Cloquet the sentinel node for the iliac/obturator node group? Cancer. 2000;6:93-97.
91. Badgwell B, Xing Y, Gershenwald JE, et al. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Ann Surg Oncol. 2007;10:2867-2875.
92. Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer. 1982;49:2420-2430.
93. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc. 1986;61:697-705.
94. Balch CM, Soong S-J, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224:255-266.
95. Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomized trial. Lancet. 1998;351:793-796.
96. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-399.
97. Gannon CJ, Rousseau DL, Ross MI, et al. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer. 2006;107:2647-2652.
98. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Ann Surg. 1999;230:453-463.
99. Johnson TM, Sondak VK, Bichakjian CK, Sabel MS. The role of sentinel lymph node biopsy for melanoma: evidence assessment. J Am Acad Dermatol. 2006;54:19-27.
100. Yu LL, Flotte TJ, Tanabe KK, et al. Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer. 1999;86:617-627.
101. Abrahamsen HN, Hamilton-Dutoit SJ, Larsen J, Steiniche T. Sentinel lymph nodes in malignant melanoma: extended histopathologic evaluation improves diagnostic precision. Cancer. 2004;100:1683-1691.
102. Kruper LL, Spitz FR, Czerniecki BJ, et al. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer. 2006;107:2436-2445.
103. Morton DL, Thompson JF, Cochran AJ, et al. Sentinelnode biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-1317.
104. Lee JH, Essner R, Torisu-Itakura H, et al. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol. 2004;22:3677-3684.
105. Sabel MS, Griffith KA, Sondak VK, et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg. 2005; 201:37-47.
106. Wagner JD, Gordon MS, Chuang T-Y, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer. 2000;89:453-462.
107. Eggermont AMM, van Geel AN, de Wilt JH, ten Hagen TL. The role of isolated limb perfusion for melanoma confined to the extremities. Surg Clin North Am. 2003;83:371-384.
108. Singletary SE, Tucker SL, Boddie AW. Multivariate analysis of prognostic factors in regional cutaneous metastases of extremity melanoma. Cancer. 1988;61:1437-1440.
109. Balch CM, Buzaid AC, Soong S-J, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
110. Minor DR, Allen RE, Alberts D, Peng Y-M, Tardelli G, Hutchinson J. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer. 1985;55:2638-2644.
111. Rochlin DB, Smart CR. Treatment of malignant melanoma by regional perfusion. Cancer. 1965;18:1544-1550.
112. McBride CM, Clark RL. Experience with l-phenylalanine mustard dihydrochloride in isolation-perfusion of extremities for malignant melanoma. Cancer. 1971;28:1293-1296.
113. Hoekstra HJ, Schraffordt Koops H, de Vries LG, et al. Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment. Cancer. 1993;72:1224-1229.
114. Bartlett DL, Ma G, Alexander HR, et al. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer. 1997;80:2084-2090.
115. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998;14:238-247.
116. Thompson JF, Kam PC. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol. 2004;88:1-3.
117. Sondak VK, Zager JS. Surgical management of locally advanced, in-transit, and metastatic melanoma. In: American Society of Clinical Oncology 2007 Educational Book. Alexandria, VA: American Society of Clinical Oncology 2007:523-527.
118. Meyer T, Merkel S, Goehl J, et al. Surgical therapy for distant metastases of malignant melanoma. Cancer. 2000;89:1983-1991.
119. Gogas H, Kirkwood JM, Sondak VK. Chemotherapy for melanoma: time for a change? Cancer. 2007;109:455-464.
120. Burke PJ, McCarthy W, Milton GW. Imidazole carboxamide therapy in advanced malignant melanoma. Cancer. 1971;27:744-750.
121. Luce JK. Chemotherapy of malignant melanoma. Cancer. 1972;30:1604-1616.
122. Asbury RF, Rosenthal SN, Descalzi ME, Ratcliffe RL, Arsenau JC. Hepatic veno-occlusive disease due to DTIC. Cancer. 1980;45:2670-2674.
123. Legha SS, Hodges C, Ring S. Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy. Cancer. 70:2018-2020.
124. Wittes RE, Wittes JT, Golbey RB. Combination chemotherapy in metastatic malignant melanoma. A randomized study of three DTIC-containing combination. Cancer. 1978;41:415-421.
125. McClay EF, Mastrangelo MJ, Sprandio JD, Bellet RE, Berd D. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer. 1989;63:1292-1295.
126. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745-2751.
127. Margolin KA, Liu P-Y, Flaherty LE, et al. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. J Clin Oncol. 1998;16:664-669.
128. Buzaid AC, Legha SS, Balch CM, et al. Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence of melanoma. Cancer. 1994;74:2476-2482.
129. Legha SS, Ring S, Papadopoulos, Plager C, Chawla S, Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer. 1989;64:2024-2029.
130. Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol. 1998;16:1752-1759.
131. Atkins MB, Hsu U, Lee S, et al. A randomized phase III trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, IL-2 and interferon alpha-2b versus cisplatin, vinblastine, dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008; in press.
132. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol. 2007;25:5426-5434.
133. Legha S, Ring S, Papadopoulos N, Raber M, Benjamin RS. A phase II trial of taxol in metastatic melanoma. Cancer. 1990;65:2478-2481.
134. Jacquillat C, Khayat D, Banzet P, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer. 1990;66:1873-1878.
135. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22:1118-1125.
136. Raymond E, Haon C, Boaziz C, Coste M. Logistic regression model of fotemustine toxicity combining independent phase II studies. Cancer. 1996;78:1980-1987.
137. Thatcher N, Lind M, Morgenstern G, et al. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. Cancer. 1989;63:1296-1302.
138. Steffens TA, Bajorin DF, Chapman PB, et al. A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma. Cancer. 1991;68:1230-1237.
139. Buzaid AC, Murren JR, Durivage HJ. High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma. Cancer. 1991;68:1238-1241.
140. Heller R, Jaroszeski MJ, Glass LF, et al. Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer. 1996;77:964-971.
141. Gottleib JA, Frei E II, Luce JK. An evaluation of the management of patients with cerebral metastases from malignant melanoma. Cancer. 1972;29:701-705.
142. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18:158-166.
143. Hwu W-J, Lis E, Menell JH, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma. Cancer. 2005;103:2590-2597.
144. Krown SE, Niedzwiecki D, Hwu W-J, Hodgson L, Hougton AN, Haluska FG. Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain. Cancer. 2006;107:1883-1890.
145. Hutchins LF, Moon J, Clark JI, et al. Evaluation of interferon alpha-2b and thalidomide in patients with disseminated malignant melanoma, phase II, SWOG 0026. Cancer. 2007;110:2269-2275.
146. Applebaum FR, Thomas ED. Treatment of acute leukemia in adults with chemoradiotherapy and bone marrow transplantation. Cancer. 1985;55(9 suppl):2202-2209.
147. McCarthy WH, Cotton G, Carlon A, Milton GW, Kossard S. Immunotherapy of malignant melanoma. Cancer. 1973; 32:97-103.
148. Gutterman J, Mavligit G, McBride C, Frei E, Hersh EM. BCG stimulation of immune responsiveness in patients with malignant melanoma. Cancer. 1973;32:321-327.
149. Twomey PL, Catalona WJ, Chretien PB. Cellular immunity in cured cancer patients. Cancer. 1974;33:435-440.
150. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709-718
151. Levy NL, Seigler HF, Shingleton WW. A multiphase immunotherapy regimen for human melanoma: clinic and laboratory results. Cancer. 1974;34:1548-1557.
152. Laucius JF, Bodurtha AJ, Mastrangelo MJ, Bellet RE. A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma. Cancer. 1977;40:2091-2093.
153. Mastrangelo MJ, Bellet RE, Berkelhammer J, Clark WH Jr. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer. 1975;36:1305-1308.
154. McKhann CF, Hendrickson CG, Spitler LE, Gunnarsson A, Banerjee D, Nelson WR. Immunotherapy of melanoma with BCG: two fatalities following intralesional injection. Cancer. 1975;35:514-520.
155. Lieberman R, Wybran J, Epstein W. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma. Cancer. 1975; 35:756-777.
156. Nathanson L, Schoenfeld D, Regelson W, Colsky J, Mittelman A. Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma. Cancer. 1979;43:1630-1635.
157. Varella AD, Bandiera CD, Amorim DE, et al. Treatment of disseminated malignant melanoma with high-dose oral BCG. Cancer. 1981;48:1353-1362.
158. Plesnicar S, Rudolf Z. Combined BCG and irradiation treatment of skin metastases originating from malignant melanoma. Cancer. 1982;50:1100-1106.
159. Krown SE, Hilal EY, Pinsky CM, et al. Intralesional injection of the methanol extraction residue of bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma. Cancer. 1978;42:2648-2660.
160. Sondak VK, Liu PY, Tuthill RJ, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol. 2002;20:2058-2066.
161. ™), compared to placebo as a post-surgical adjuvant in AJCC stage IV melanoma. Ann Surg Oncol. 2006;13(suppl):5.
162. Bystryn JC, Oratz R, Harris MN, Roses DF, Golomb FM, Speyer JL. Immunogenicity of a polyvalent melanoma antigen vaccine in humans. Cancer. 1988;61:1065-1070.
163. Sosman JA, Weeraratna AT, Sondak VK. When will melanoma vaccines be proven effective? J Clin Oncol. 2004; 22:387-389.
164. Cassel WA, Murray DR, Torbin AH, Olkowski ZL, Moore ME. Viral oncolysate in the management of malignant melanoma. Cancer. 1977;40:672-679.
165. Wallack MK, McNally KR, Leftheriotis E, et al. A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates. Cancer. 1986;57:649-655.
166. Merigan TC, DeClercq E, Finkelstein MS, et al. Clinical studies employing interferon inducers in man and animals. Ann NY Acad Sci. 1970;173:746-759.
167. Retsas S, Priestman TJ, Newton KA, Westbury G. Evaluation of human lymphoblastoid interferon in advanced malignant melanoma. Cancer. 1983;51:273-276.
168. Creagan ET, Ahmann DL, Green SJ, et al. Phase II study of recombinant leukocyte A interferon (rIFN-αA) in disseminated malignant melanoma Cancer. 1984;54:2844-2849.
169. Creagan ET, Ahmann DL, Frytak S, Long HJ, Itri LM. Recombinant leukocyte A interferon (rIFN-αA) in the treatment of disseminated malignant melanoma. Cancer. 1986;58:2576-2578.
170. Dorval T, Palangie T, Jouve M, et al. Clinical phase II trial of recombinant DNA interferon (interferon alfa 2b) in patients with metastatic malignant melanoma. Cancer. 1986;58:215-218.
171. Sondak VK. How does interferon work? Does it even matter? Cancer. 2002;95:947-949.
172. Margolin KA. Biochemotherapy for melanoma: rational therapeutics in the search for weapons of melanoma destruction. Cancer. 2004;101:435-438.
173. Keilholz U, Scheibenbogen C, Tilgen W, et al. Interferon-α and interleukin-2 in the treatment of metastatic melanoma: comparison of two phase II trials. Cancer. 1993; 72:607-614.
174. Eton O, Talpaz M, Lee KH, Rothberg JM, Brell JM, Benjamin RS. Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a. Implications for the treatment of patients with metastatic melanoma. Cancer. 1996; 77:893-899.
175. Eton O, Buzaid AC, Bedikian AY, et al. A phase II study of "decrescendo" interleukin-2 plus interferon-α-2a in patients with progressive metastatic melanoma after chemotherapy. Cancer. 2000;88:1703-1709.
176. Hollinshead A, Arlen M, Yonemoto R, et al. Pilot studies using melanoma tumor-associated antigens (TAA) in specific-active immunochemotherapy of malignant melanoma. Cancer. 1982;49:1387-1404.
177. Minasian LM, Yao TJ, Steffens TA, et al. A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. Cancer. 1995; 75:2251-2257.
178. Livingston P. Ganglioside vaccines with emphasis on GM2. Semin Oncol. 1998;25:636-645.
179. Abdel-Wahab Z, Weltz C, Hester D, et al. A phase I clinical trial of immunotherapy with interferon-γ gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer. 1997;80:401-412.
180. Markovic SN, Suman VJ, Rao RD, et al. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma. Cancer. 2007;110:203-214.
181. Tagawa ST, Cheung E, Banta W, Gee C, Weber JS. Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with stage IV melanoma. Cancer. 2006;106:1353-1357.
182. Tagawa ST, Lee P, Snively J, et al. Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with stage IV melanoma. Cancer. 2003;98:144-154.
183. Reuben JM, Lee BN, Li C, et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer. 2006;106:2437-2444.
184. Childs RW. Nonmyeloablative allogeneic peripheral blood stem-cell transplantation as immunotherapy for malignant diseases. Cancer J. 2000;6:179-187.
185. Margolin KA. Autologous and allogeneic high-dose therapy for melanoma. Curr Oncol Rep. 2001;3:338-343.
186. Slankard-Chahinian M, Holland JF, Gordon RE, Becker J, Ohnuma T. Adoptive autoimmunotherapy: cytotoxic effect of an autologous long-term T-cell line on malignant melanoma. Cancer. 1984;53:1066-1072
187. Rayner AA, Grimm EA, Lotze MT, Chu EW, Rosenberg SA. Lymphokine-activated killer (LAK) cells. Cancer. 1985;55:1327-1333.
188. Dillman RO, Oldham RK, Barth NM, et al. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. Cancer. 1991;68:1-8.
189. Dillman RO, Church C, Oldham RK, West WH, Schwartzberg L, Birch R. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer: the National Biotherapy Study Group experience. Cancer. 1993;71:2358-2370.
190. Keilholz U, Schlag P, Tilgen W, et al. Regional administration of lymphokine-activated killer cells can be superior to intravenous application. Cancer. 1992;69:2172-2175.
191. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889-897.
192. Legha SS, Gianan MA, Plager C, Eton OE, Papadopoulous NEJ. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer. 1996;77:89-96.
193. Eton O, Rosenblum MG, Legha SS, et al. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma. Cancer. 2002;95:127-134.